Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
|ClinicalTrials.gov Identifier: NCT01646593|
Expanded Access Status : No longer available
First Posted : July 20, 2012
Last Update Posted : December 15, 2014
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.
|Condition or disease||Intervention/treatment|
|Gastrointestinal Stromal Tumors||Drug: Regorafenib (BAY73-4506)|
|Study Type :||Expanded Access|
|Official Title:||An Open-label Expanded Access Program of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib|
- Drug: Regorafenib (BAY73-4506)
160 mg BAY73-4506, 3 weeks on drug, 1 week off
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01646593
|Study Director:||Bayer Study Director||Bayer|